argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company's lead product candidates include ARGX-113 that completed Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis, immune thrombocytopenia, and pemphigus vulgaris; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome.
Read More…
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Phone329-310-3400
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$25.37 million
Profitability
Miscellaneous
Employees103
Next Earnings DateN/A
OptionableOptionable
argenx (NASDAQ:ARGX) Frequently Asked Questions
What is argenx's stock symbol?
argenx trades on the NASDAQ under the ticker symbol "ARGX."
What price target have analysts set for ARGX?
11 brokerages have issued 12 month target prices for argenx's stock. Their predictions range from $110.00 to $182.00. On average, they expect argenx's stock price to reach $158.75 in the next twelve months. This suggests a possible upside of 26.6% from the stock's current price. View Analyst Price Targets for argenx.
What is the consensus analysts' recommendation for argenx?
11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for argenx in the last year. There are currently 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for argenx.
What are Wall Street analysts saying about argenx stock?
Here are some recent quotes from research analysts about argenx stock:
- 1. According to Zacks Investment Research, "argenx SE is a biopharmaceutical company. It focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company's product pipeline consists of ARGX-113, ARGX-110 and ARGX-111 which are in clinical trials. argenx SE is based in Breda, the Netherlands. " (9/16/2019)
- 2. Stifel Nicolaus analysts commented, "We are reiterating our Buy rating on ARGX shares after the company reported its 2Q19 financials and business update. While we acknowledge the valuation at these levels and the relatively quiet catalyst calendar over the next several months, we continue to view ARGX’s efgartigimod as best positioned in the anti-FcRn class given: (1) its first mover advantage; (2) its ability to be dosed via a low dose, subcutaneous injection for potential chronic therapy; and (3) it has generated proof-of-concept data in three indications (gMG, ITP, PV) and has been well tolerated, the latter of which differentiates it from other programs in the class. So we’d own the stock." (8/1/2019)
Has argenx been receiving favorable news coverage?
News coverage about ARGX stock has been trending somewhat negative on Monday, according to InfoTrie Sentiment. The research group identifies positive and negative press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. argenx earned a media sentiment score of -1.3 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the next several days. View News Stories for argenx.
Who are some of argenx's key competitors?
Some companies that are related to argenx include NOVOZYMES A/S/S (NVZMY), Seattle Genetics (SGEN), Neurocrine Biosciences (NBIX), Qiagen (QGEN), BIO-TECHNE (TECH), Moderna (MRNA), bluebird bio (BLUE), Adaptive Biotechnologies (ADPT), China Biologic Products (CBPO), Repligen (RGEN), Allogene Therapeutics (ALLO), Spark Therapeutics (ONCE), Ablynx (ABLYF), Crispr Therapeutics (CRSP) and Iovance Biotherapeutics (IOVA).
What other stocks do shareholders of argenx own?
Who are argenx's key executives?
argenx's management team includes the folowing people:
- Mr. Tim Van Hauwermeiren, CEO & Exec. Director (Age 47)
- Mr. Eric Castaldi, Chief Financial Officer (Age 55)
- Prof. Hans de Haard, Chief Scientific Officer (Age 59)
- Mr. Dirk Marcel Leon Beeusaert, Gen. Counsel (Age 55)
- Dr. Torsten Dreier, Chief Devel. Officer (Age 55)
When did argenx IPO?
(ARGX) raised $65 million in an initial public offering on Thursday, May 18th 2017. The company issued 3,600,000 shares at a price of $18.18 per share. Cowen and Company and Piper Jaffray acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.
Who are argenx's major shareholders?
argenx's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Price T Rowe Associates Inc. MD (11.83%), EcoR1 Capital LLC (1.81%), Jennison Associates LLC (1.17%), Jennison Associates LLC (1.17%), Eaton Vance Management (1.07%) and Janus Henderson Group PLC (0.97%).
Which institutional investors are selling argenx stock?
ARGX stock was sold by a variety of institutional investors in the last quarter, including EcoR1 Capital LLC, Jennison Associates LLC, Jennison Associates LLC, Cormorant Asset Management LP, Marshall Wace North America L.P., Morgan Stanley, Janus Henderson Group PLC and Janus Henderson Group PLC.
Which institutional investors are buying argenx stock?
ARGX stock was bought by a variety of institutional investors in the last quarter, including Price T Rowe Associates Inc. MD, Boxer Capital LLC, Eaton Vance Management, Point72 Asset Management L.P., Renaissance Technologies LLC, University of Notre Dame DU Lac, Bank of Montreal Can and Artal Group S.A..
How do I buy shares of argenx?
Shares of ARGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is argenx's stock price today?
One share of ARGX stock can currently be purchased for approximately $125.37.
How big of a company is argenx?
argenx has a market capitalization of $4.78 billion and generates $25.37 million in revenue each year. The company earns $-78,700,000.00 in net income (profit) each year or ($2.35) on an earnings per share basis. argenx employs 103 workers across the globe.View Additional Information About argenx.
What is argenx's official website?
How can I contact argenx?
argenx's mailing address is Willemstraat 5, Breda P7, 4811 AH. The company can be reached via phone at 329-310-3400 or via email at [email protected]
MarketBeat Community Rating for argenx (NASDAQ ARGX)
MarketBeat's community ratings are surveys of what our community members think about argenx and other stocks. Vote "Outperform" if you believe ARGX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARGX will underperform the S&P 500 over the long term. You may vote once every thirty days.
